Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry|February 5, 2010
Mitochondrial biotransformation of omega-(phenoxy)alkanoic acids, 3-(phenoxy)acrylic acids, and omega-(1-methyl-1H-imidazol-2-ylthio)alkanoic acids: a prodrug strategy for targeting cytoprotective antioxidants to mitochondriaKurt S Roser, Paul S Brookes, Andrew P Wojtovich, et al.
Human Mutation|March 25, 1999
Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutationsR P Ketterling, J B Drost, W A Scaringe, et al.
Blood|May 1, 1989
Functional consequences of an arginine180 to glutamine mutation in factor IX HiloD M Monroe, D M McCord, M N Huang, et al.
Blood|July 1, 1985
Distinctive lymphocyte subpopulation abnormalities in patients with congenital coagulation disorders who exhibit lymph node enlargementH E Prince, J K Kreiss, C K Kasper, et al.
Human Mutation|September 12, 2000
Novel hotspot detector software reveals a non-CpG hotspot of germline mutation in the factor IX gene (F9) in Latin AmericansJ B Drost, W A Scaringe, A R Jaloma-Cruz, et al.
The Journal of Biological Chemistry|July 5, 1989
Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding propertiesJ Ware, D L Diuguid, H A Liebman, et al.
Human Molecular Genetics|March 1, 1993
Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-CaucasiansB Gostout, E Vielhaber, R P Ketterling, et al.
Thrombosis and Haemostasis|December 2, 1991
In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentratesC K Kasper, H C Kim, E D Gomperts, et al.
The Journal of Biological Chemistry|February 16, 1996
Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIaP J Larson, S A Stanfield-Oakley, W J VanDusen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 24, 1999
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study GroupJ M Lusher, H R Roberts, G Davignon, et al.
Pageof 12